BioRestorative Therapies, Inc. (BRTX) vs iSpecimen Inc. (ISPC)
A side-by-side comparison of BioRestorative Therapies, Inc. and iSpecimen Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BRTX
BioRestorative Therapies, Inc.
$2.23HealthcareDelayed quote: Oct 6, 2026, 12:04 PM EDT
ISPC
iSpecimen Inc.
$1.04HealthcareDelayed quote: Oct 6, 2026, 12:30 PM EDT
Total return — BRTX vs ISPC
growth of $100 · dividends reinvested · last 5yBRTX -99.6% (-67.2%/yr)ISPC -100.0% (-82.1%/yr)BRTX compounded faster over this window
Log scale — wide-divergence pair
BRTX ISPC
BRTX vs ISPC: by the numbers
- •BRTX is the larger company ($3M vs $3M market cap).
- •Both run net losses; ISPC's is the smaller (-2449.04% vs -3089.55% net margin).
- •BRTX grew revenue faster over the past five years (38.99% vs -46.70% CAGR).
Metrics side by side
Valuation
| Metric | BRTX | ISPC |
|---|---|---|
| P/S ratio | 8.59 | 5.62 |
| P/B ratio | 1.02 | 1.51 |
Profitability
| Metric | BRTX | ISPC |
|---|---|---|
| Gross margin | 92.09% | 1.25% |
| Operating margin | -4350.05% | -465.42% |
| Net margin | -3089.55% | -2449.04% |
| ROE | -365.43% | -657.69% |
| ROIC | -464.86% | -476.39% |
Growth (annualized)
| Metric | BRTX | ISPC |
|---|---|---|
| Revenue CAGR (5Y) | 38.99% | -46.70% |
| Total return CAGR (5Y) | -61.44% | -81.14% |
Frequently asked
- Which has grown faster, BRTX or ISPC?
- Over the past five years, BRTX grew revenue faster — BRTX at a 38.99% CAGR versus ISPC at -46.70%.
- How have BRTX and ISPC total returns compared?
- Over the past 5 years, BRTX delivered -61.44% and ISPC delivered -81.14% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
BioRestorative Therapies ROEiSpecimen ROEBioRestorative Therapies operating marginiSpecimen operating marginBioRestorative Therapies revenue growthiSpecimen revenue growthBioRestorative Therapies free cash flowiSpecimen free cash flow
BioRestorative Therapies & iSpecimen appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.